Amgen reported cash flows from operating activities of USD 10.00 billion for the full year 2025. The company invested USD 1.90 billion in capital expenditures to enhance and expand its manufacturing network during the period. Amgen retired USD 6.00 billion of debt and increased its quarterly cash dividend by 6 percent to USD 2.38 per share of common stock for 2025. In December 2025, the Board of Directors declared a cash dividend of USD 2.52 per share for the first quarter of 2026, representing a 6 percent increase over the same period in the prior year, to be paid in March 2026. Cost of sales for 2024 increased to 38.5 percent of total revenues, primarily driven by higher amortization expense from Horizon acquisition-related assets and higher profit share and royalty expenses. The impact was partially offset by changes in product sales mix, including the addition of acquired Horizon products. Amgen continues to focus on research and development activities across three key areas: Research and Early Pipeline, Later-Stage Clinical Programs, and Marketed Product Support. The company’s principal products include Prolia, Repatha, Otezla, Enbrel, Evenity, and Xgeva. Amgen emphasized its ongoing strategy of investing in innovative medicines and human capital management to support its global workforce and business growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000318154-26-000010), on February 13, 2026, and is solely responsible for the information contained therein.